Atopic Dermatitis - Treatment Response EVALuation and UsEr Satisfaction with Tralokinumab in Standard Clinical Practice in Japan

Atopic Dermatitis - Treatment Response EVALuation and UsEr Satisfaction with Tralokinumab in Standard Clinical Practice in Japan - The ADValue Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061150

Enrollment

300

Registered

2026-04-08

Start date

2026-04-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed AD requiring systemic drug therapy 2. Initiating treatment with tralokinumab according to the treating physician's decision 3. Patients >= 15 years of age 4. Written informed consent obtained prior to enrolment, as follows: -Patients aged >= years: obtained directly from the patient. -Patients aged 15 to 17 years: obtained from the legal guardian, and written assent is additionally obtained from the adolescent who is capable of forming an opinion and understanding the information provided.

Exclusion criteria

Exclusion criteria: 1.Enrolment in an interventional study 2.Prior enrolment in this study 3.Prior treatment with tralokinumab (including prior use in a clinical trial). 4.Lack of capability by patient/or caregiver to give informed consent

Design outcomes

Primary

Measure	Time frame
To assess disease control after 52 weeks of treatment with tralokinumab based on patient-reported outcome measures.	—

Countries

Japan,Europe

Contacts

Public ContactMotohiro Honda

EBC&M LLC Clinical Division

crs5-info@ebc-m.com0364353833

Outcome results